
Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00.
Shares of Galmed Pharmaceuticals are trading down 22.69% over the last 24 hours, at $0.94 per share.

Raymond James has decided to maintain its Outperform rating of Galmed Pharmaceuticals (NASDAQ:GLMD) and lower its price target from $14.00 to $5.00.
Shares of Galmed Pharmaceuticals are trading down 22.69% over the last 24 hours, at $0.94 per share.